Mode
Text Size
Log in / Sign up

System-level barriers linked to delays and poorer survival in 1,100 women with primary breast cancerDistance and cost drive higher breast cancer death rates

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that system-level barriers are associated with delays and poorer survival in women with breast cancer.

This retrospective cohort study analyzed data from hospital records, cancer registries, and administrative databases involving 1,100 women diagnosed with primary breast cancer. The investigation assessed individual, community, and health system level determinants including geographic, financial, and system-level barriers, care at tertiary centers, and patient navigation support. The primary outcome was survival, with secondary outcomes including screening access, diagnostic and treatment timeliness, adherence to therapy, treatment non-completion, and advanced-stage presentation.

Results indicated that over one-third of patients had never undergone prior screening. Additionally, 25% traveled more than 25 km to access services. Diagnostic delays exceeding 60 days occurred in nearly one-third of patients, and one-quarter experienced treatment initiation delays. Overall treatment adherence was 72.1%, with lower adherence observed among uninsured patients. Mortality at follow-up was 32.5% in the low-access group, whereas survival was greater than 90% in the high-access group.

Geographic, financial, and system-level barriers were independently associated with delays, treatment non-completion, and poorer survival. Conversely, care at tertiary centers and patient navigation support were significantly associated with improved timeliness, adherence, and survival outcomes. Safety data, adverse events, and discontinuations were not reported in this observational study. Limitations regarding causality and specific follow-up duration were not reported. Strengthening healthcare access, expanding patient navigation, and enhancing system coordination may reduce delays, improve adherence, and improve survival.

Many women face a choice between their health and their wallet. Some must drive hours just to see a doctor for a routine checkup. This struggle is not just about inconvenience. It is about life and death.

Breast cancer affects millions of women every year. It is the most common cancer among women worldwide. Early detection saves lives. But many people miss the window for early care.

This doesn't mean this treatment is available yet.

Old thinking blamed patients for not showing up on time. We assumed they did not care enough or forgot their appointments. But new evidence suggests the system failed them first.

The real problem lies in where people live and how much money they have. Rural areas often lack specialists. Low-income families struggle with travel costs. These barriers stack up against each other.

The hidden cost of distance

Imagine a patient living far from a hospital. She needs a mammogram. The nearest facility is 50 miles away. She must take time off work. She must pay for gas. She must find childcare.

These hurdles feel small individually. Together they become a wall. Many women simply give up. They skip the screening. They wait until symptoms appear.

By the time symptoms show, the cancer is often advanced. Advanced cancer is harder to treat. It costs more money. It requires more time away from family.

How access changes survival

A recent study looked at over 1,100 women with breast cancer. They tracked screening history and treatment timelines. They also looked at where patients lived and how they paid for care.

The results were stark. One-third of patients had never been screened before. One-quarter had to travel more than 25 kilometers to get help. These numbers tell a clear story.

Distance matters. Money matters. Insurance status matters.

Women who traveled far waited longer for diagnosis. They waited longer to start treatment. They were less likely to finish their therapy. This pattern held true even after adjusting for age and other factors.

The gap between groups

The study split patients into two main groups. One group had high access to care. The other had low access. The difference in survival was massive.

Women in the high-access group had over 90 percent survival rates. Women in the low-access group had a 32.5 percent mortality rate. That is a gap of nearly 60 percentage points.

This is not just about biology. It is about logistics. It is about whether a woman can get to a clinic when she needs to.

Support systems make a difference

Some factors helped patients overcome these barriers. Care at tertiary centers improved outcomes. Patient navigation support also helped significantly.

Patient navigators act as guides. They help schedule appointments. They explain insurance paperwork. They remind patients about follow-up visits.

These helpers bridge the gap between the patient and the hospital. They reduce the confusion that often leads to delays.

Navigation support significantly improved timeliness and adherence.

Uninsured patients struggled the most with treatment adherence. Only 72.1 percent of all patients completed their therapy. The number dropped lower for those without insurance.

Financial toxicity is a real term in oncology. It means the cost of treatment hurts the patient so much they stop care. This is a systemic failure.

If you live in a rural area, you might face these barriers. You should know your rights and options. Ask about patient navigation services at your local hospital.

Talk to your doctor about travel assistance programs. Some centers offer grants or vouchers for gas. They may have telehealth options for follow-ups.

Do not wait for symptoms to appear. Schedule your screening even if it means driving further. Your health is worth the trip.

Limitations and next steps

This study looked at records from 2022 to 2024. It focused on women diagnosed with primary breast cancer. It did not track every single patient in the country.

The findings highlight a need for better infrastructure. They do not offer a magic fix. Changing health systems takes time and money.

Future research will test specific interventions. We need to know which support programs work best. We need to know how to scale them up.

The goal is to make care equal for everyone. Distance should not decide who lives or dies. Cost should not stop a woman from getting help.

We are moving toward a system where access is guaranteed. Until then, awareness and navigation remain key tools.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Disparities in public health infrastructure, healthcare access, and system-level support contribute to delays in breast cancer screening, diagnosis, treatment initiation, and adherence to care, leading to advanced-stage presentation and poorer survival, particularly among rural and underserved populations. To evaluate the influence of individual, community, and health system level determinants on screening access, timeliness of diagnosis and treatment, adherence to therapy, and survival outcomes among women with breast cancer. This retrospective cohort study included 1,100 women diagnosed with primary breast cancer between January 2022 and December 2024. Data were obtained from hospital records, cancer registries, and administrative databases. Screening history, diagnostic and treatment intervals, treatment adherence, and survival were assessed. Multivariable logistic regression identified determinants of screening access, diagnostic and treatment delays, and treatment non-completion, while Cox proportional hazards models evaluated survival after adjustment for confounders. Over one-third of patients had never undergone prior screening, and 25% traveled more than 25 km to access services, indicating that geographic and access barriers may contribute to delayed diagnosis and poorer survival. Diagnostic delays exceeding 60 days occurred in nearly one-third of patients, and one-quarter experienced treatment initiation delays. Overall treatment adherence was 72.1%, with lower adherence among uninsured patients. Integrated pathway analysis identified a low-access group (28.3%) characterized by absent screening, who had prolonged delays at each stage of care and a 32.5% mortality at follow-up, and reduced survival, whereas the high-access group demonstrated >90% survival at follow-up. Geographic, financial, and system-level barriers were independently associated with delays, treatment non-completion, and poorer survival. In contrast, care at tertiary centers and patient navigation support were significantly associated with improved timeliness, adherence, and survival outcomes. Social and system-level determinants exert cumulative effects across the breast cancer care continuum. Strengthening healthcare access, expanding patient navigation, and enhancing system coordination may reduce delays, improve adherence, and improve survival.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.